AUTHOR=Alabi Babatunde Adebola , Nku-Ekpang Okot-Asi , Lawal Sodiq Kolawole , Iwalewa Ezekiel Olugbenga , Omobowale Temidayo , Ajike Richard , Lawal Ridwan Abiodun 

TITLE=Mitigative role of cysteamine against unilateral renal reperfusion injury in Wistar rats

JOURNAL=Frontiers in Pharmacology

VOLUME=15

YEAR=2024

URL=https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2024.1456903

DOI=10.3389/fphar.2024.1456903

ISSN=1663-9812

ABSTRACT=<sec><title>Background</title><p>Ischemia-reperfusion injury (IRI) is unavoidable during kidney transplant and it is responsible for delayed or non-function after kidney transplantation. Cysteamine is the standard drug in the management of nephropathic cystinosis and its extra-renal complications. Thus, we designed this study to investigate its potential against renal reperfusion injury.</p></sec><sec><title>Results</title><p>Significant elevation of H<sub>2</sub>O<sub>2,</sub> MDA, and nitrite and reduced GPx, GSH, and protein thiol in the Ischemia-reperfusion injury rats was reversed by cysteamine (50 and 100 mg/kg). Serum MPO, TNF-α, IL-1β, creatinine, and AOPP were significantly elevated in IRI while rats treated with cysteamine revealed a significant decrease (<italic>p</italic> &lt; 0.05) in the activities of these pro-inflammatory and renal injury markers.</p></sec><sec><title>Conclusion</title><p>Based on its activity against inflammation, apoptosis, and free radical-induced stress, cysteamine has great potential to be used as a kidney transplant pre-operative drug to prevent renal reperfusion injury.</p></sec>